<DOC>
	<DOCNO>NCT00427167</DOCNO>
	<brief_summary>This study evaluate safety immune response healthy volunteer experimental malaria vaccine call AMA1-C1/Alhydrogel® ( Registered Trademark ) + CPG 7909 . Malaria infection red blood cell cause parasite , Plasmodium falciparum , spread certain kind mosquito . Each year , 1 million people kill malaria worldwide , young child Africa . AMA1 C1 may help block malaria parasite get red blood cell . The vaccine mixed Alhydrogel® ( Registered Trademark ) , material commonly add vaccine make work better ( also call adjuvant ) . Besides evaluate vaccine , study also test two solution experimental adjuvant , CPG 7909-P CPG 7909-S . Healthy people 18 50 year age may eligible 7-month study . Participants randomly assign one four treatment group ( A , B , C D ) . All receive two vaccination , give shot upper arm either 1 2 month apart , show : - Group A : AMA1 CI/Alhydrogel® ( Registered Trademark ) /CPG 7909-P Day 0 Day 28 ( 1-month interval ) - Group B : AMA1 CI/Alhydrogel® ( Registered Trademark ) /CPG 7909-S Day 0 Day 28 ( 1-month interval ) - Group C : AMA1 CI/Alhydrogel® ( Registered Trademark ) /CPG 7909-P Day 0 Day 56 ( 2-month interval ) - Group D : AMA1 CI/Alhydrogel® ( Registered Trademark ) /CPG 7909-S Day 0 Day 56 ( 2-month interval ) Group A B participant return clinic checkup 3 , 7 , 14 day vaccination month 2 , 3 , 4 , 5 , 7 . Group C D participant come clinic 3 , 7 , 14 day vaccination month 3 , 4 , 5 , 7 . In addition vaccination , study include follow procedure : - Photographs subject 's arm vaccination give rash develops . - Daily temperature symptom record first 6 day 2 vaccination , time concern fever symptom . - Blood draw 12 time study check safety measure antibody response effect study vaccine . Some participant may ask undergo plasmapheresis , procedure collect plasma , liquid part blood . This do use machine call blood cell separator . Blood collect needle place ...</brief_summary>
	<brief_title>Phase I Study AMA1-C1/Alhydrogel® ( Registered Trademark ) + CPG 7909 Malaria Vaccine</brief_title>
	<detailed_description>AMA1-C1 + CPG 7909 blood stage malaria vaccine candidate . The objective Phase 1 study confirm previously demonstrate safety immunogenicity AMA1-C1 + CPG 7909 formulate phosphate buffer . In addition , study evaluate safety immunogenicity AMA1-C1 + CPG 7909 formulate saline buffer , determine addition CPG 7909 saline buffer enhance immune response AMA1-C1 manner similar see addition CPG 7909 phosphate buffer . The immunological effect give second dose vaccine 1 2 month also evaluate . The study double blind Phase 1 clinical trial healthy adult volunteer . Volunteers screen 24 participant enrol randomly assign 1 4 group 2x2 design : 6 volunteer receive 2 dos 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG 7909 ( phosphate ) 1-month dose interval ; 6 volunteer receive 2 dos 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG 7909 ( saline ) 1 month dose interval ; 6 volunteer receive 2 dos 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG 7909 ( phosphate ) 2-month dose interval ; 6 volunteer receive 2 dos 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG 7909 ( saline ) 2 month dose interval . Safety outcome measure local systemic ( include laboratory ) adverse event . Immune responses vaccination measure enzyme-linked immunosorbent assay ( ELISA ) parasite growth inhibition assay ( GIA ) , compare among group .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 50 year , inclusive . Good general health determine review medical history and/or clinical test screen . Available duration trial ( 30 week ) . Willingness participate study evidence sign informed consent document . EXCLUSION CRITERIA : 1 . Pregnancy determine positive urine betahCG time study ( female ) . 2 . Participant unwilling use reliable contraception method least 2 week prior vaccination duration trial . Reliable method birth control include : pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; surgical sterilization ; vaginal ring ; intrauterine device ; abstinence ; postmenopause ( female ) . 3 . Currently breastfeed ( female ) . 4 . Behavioral , cognitive , psychiatric disease opinion investigator affect ability participant understand cooperate study protocol . 5 . Neutropenia define absolute neutrophil count le 1500/mm ( 3 ) . 6 . Alanine aminotransaminase ( ALT ) level laboratorydefined upper limit normal . 7 . Serum creatinine level laboratorydefined upper limit normal . 8 . Hemoglobin laboratorydefined low limit normal , sex . 9 . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , endocrine , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study include urinalysis . 10 . Other condition opinion investigator would jeopardize safety right participant participate trial would render subject unable comply protocol . 11 . History receive investigational product within past 30 day . 12 . Participant medical , occupational family problem result alcohol illicit drug use past 12 month . 13 . History severe allergic reaction anaphylaxis . 14 . Positive ELISA confirmatory Western blot test HIV1 . 15 . Positive ELISA confirmatory immunoblot test hepatitis C virus ( HCV ) . 16 . Positive hepatitis B surface antigen ( HBsAg ) ELISA . 17 . Preexisting autoimmune antibodymediated disease include limited : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia . 18 . Known immunodeficiency syndrome . 19 . Positive serum antidsDNA titer . 20 . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study . 21 . Receipt live vaccine within past 4 week kill vaccine within past 2 week prior entry study . 22 . History surgical splenectomy . 23 . Receipt blood product within past 6 month . 24 . Previous receipt investigational malaria vaccine . 25 . Receipt antimalarial prophylaxis past 12 month , receipt chloroquine relate compound ( amodiaquine primaquine ) previous 8 week prior study entry . 26 . Prior malaria infection . 27 . Any medical , psychiatric , social , occupational condition responsibility , judgment Principal Investigator ( PI ) , would interfere evaluation study objective . 28 . History know allergy nickel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 3, 2009</verification_date>
	<keyword>Blood Stage</keyword>
	<keyword>Investigational</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Malaria</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>